Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

Medarex and Novartis licensing agreement for HuMAb-Mouse technology

Nov. 16, 1998

Novalon signs research agreement with Millennium

Nov. 16, 1998

S-18127 characterized as a selective, structurally novel 5-HT1B/1D receptor antagonist

Nov. 12, 1998

Sangamo enters agreement with Zeneca for identification of novel gene targets

Nov. 10, 1998

MitoKor and Pfizer to collaborate on mitochondrial targets for neurodegenerative diseases

Nov. 10, 1998

Corixa invests in, works with ImmGenics to develop high-potency monoclonal antibodies

Nov. 9, 1998

Dutch research group focuses attention on adenosine A3 receptor ligands

Nov. 5, 1998

Step taken toward European protection for AltaRex's fundamental technology platform

Nov. 5, 1998

GenVec receives expanded patent coverage in field of gene therapy

Nov. 4, 1998

New agreement between Pharmacopeia and Schering-Plough expands R&D collaboration

Nov. 4, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...